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were compared and settled through consensus. A random-effects
meta-analytic model was applied in all calculations. Jadad’s scale
assessed study quality of reporting. RESULTS: A total of 50
potential studies were identiﬁed. Thirty-ﬁve were excluded and
15 were evaluated. Quality of reporting of included studies was
on average 59  24%. All three drugs showed beneﬁcial effects
in preventing all SREs over placebo in cancer patients with
bone metastasis. Zoledronate was the pharmacological strategy
reporting the lowest relative risk (RR = 0.67; CI95% = 0.55,
0.81; N = 695), followed by pamidronate (RR = 0.79;
CI95% = 0.71, 0.88, N = 1951), and clodronate (RR = 0.87;
CI95% = 0.75, 1.00; N = 681). However, no clear advantage of
one drug over the others was observed since conﬁdence intervals
overlapped substantially. All targeted bisphosphonates showed
no beneﬁts over placebo in reducing the number of deaths in a
12-month period (p > 0.05). CONCLUSION: Clodronate, pam-
idronate, and zoledronate are able to reduce the morbidity of
patients with bone metastasis in regards to SREs but not overall
mortality.
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OBJECTIVE: To assess the potential value of trastuzumab (T) to
society, we initially assessed the long-term impact of T treatment
in early breast cancer (EBC) on the annual number of patients
developing metastatic BC (MBC) from 2005–2015 in ﬁve Euro-
pean countries. METHODS: Annual EBC incidence for 2003–
2015 was projected by applying stage-speciﬁc proportions for
stages I-III, according to regional registry data, to published
female BC incidence rates from 1990–2002. Age-speciﬁc rates for
2002 were then applied to United Nations 2003–2015 popula-
tion projections. The annual number of patients with HER2-
positive MBC includes de novo MBC incidence plus patients with
BC recurrence. The baseline 10-year recurrence rate for standard
treatment was estimated as 37%, based on 4-year follow-up in
the control arm of a combined trial analysis in patients with
HER2-positive BC and the long-term timing of recurrence in all
patients with BC. To model recurrence in T-treated EBC patients,
the hazard ratio at median 1-year follow-up in the HERA trial
(0.49; 95% conﬁdence interval [CI]: 0.38, 0.63) was applied,
resulting in an estimated 10-year recurrence rate of 18.1% (95%
CI: 14.0, 23.3). RESULTS: In 2004, prior to T approval for EBC,
the pool of de novo and relapsed MBC patients was estimated at
16,156. Between 2005 and 2015, the model predicts that T
treatment will result in an annual decline of 2.5% (95% CI: 1.7,
3.2). The total number of patients prevented from developing
metastases over 10 years is projected to be 27,727 (95% CI:
20,116, 33,709). CONCLUSION: T is expected to prevent
nearly 28,000 women from developing MBC over a 10-year
period in ﬁve countries alone and should considerably reduce the
health resource burden of MBC treatment.
PCN7
ANALYSIS OF MASTECTOMY IN BREAST
CANCERTREATMENT
Ugiliweneza B
University of Louisville, Louisville, KY, USA
OBJECTIVE: Surgery is main treatment used in most early breast
cancer cases; surgery is the primary treatment for breast cancer to
remove as many as cancer cells as possible. There are two types
of surgeries: mastectomy and lumpectomy. Studies have shown
that mastectomy is the most performed in comparison to lumpec-
tomy. With our data, out of 1485 cases of breast cancer, 146 were
primarily treated by mastectomy while only 26 were treated with
lumpectomy. We analyzed, in detail, the information on mastec-
tomy as a treatment option for breast cancer to compare the use
of different types of mastectomy and to study the cost of the most
frequent types. METHODS: We used the 2004 data from the
National Inpatient Sample (NIS). We ﬁrst ﬁltered the data with
respect to the main types of mastectomy: radical mastectomy,
modiﬁed radical mastectomy, simple (total) mastectomy, and the
subcutaneous mastectomy. Second, we analyzed them with
summary statistics using SAS, and then ﬁnally, we looked at the
cost of the most frequent by plotting the actual costs and the
future trend. We used SAS Text Miner to compress patient diag-
noses, and compare them to the types of treatment. RESULTS:
The modiﬁed radical mastectomy is the most frequently used in
treating breast cancer with 81.5% of the total mastectomies.
Then, we have the simple (total) mastectomy with 13.7%.
Finally, we have the subcutaneous mastectomy (2.7%) and the
radical mastectomy (2.1%). The cost of the modiﬁed radical
mastectomy has a constant trend of around $20,000. CONCLU-
SION: The modiﬁed radical mastectomy is the most performed
so far in the treatment of breast cancer by mastectomy. SAS can
be used to study health care cases.
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OBJECTIVE: Glioblastoma multiforme (GBM) accounts for
35% of primary brain tumor in Taiwan. The objective of this
study is to determine if patients with GBM survived longer after
adjuvant therapy by temozolomide. METHODS: We collected all
inpatients of GBM veriﬁed with pathology in Chang Gung
Memorial Hospital from January 2001 to March 2006. Patients
aged more than 80 at diagnosis were excluded. Outcome was
followed until December 31, 2006. Survival analysis was per-
formed by Kaplan-Meier estimation method and Cox regression
model and explores the effect related to various prognostic
factors including adjuvant therapy of temozolomide. RESULTS:
There were 66 temozolomide users and 133 non-users during the
study period. They were no statistical signiﬁcant differences on
gender, age at diagnosis and year of diagnosis between these two
groups. Analysis showed 50% survival for users and non-users
were 18.7 and 9.9 months, respectively (Log-rank test,
p < 0.0001). The hazard ratio was 2.58 (95% conﬁdence inter-
val, 1.60–4.16) for the aged 60–80 compared with patients aged
20–40, and that of temozolomide treatment was 0.47 (.34–.66).
Stratiﬁed analysis showed that there was no signiﬁcant difference
in survival between patients with concomitant radiotherapy.
CONCLUSION: The adjuvant therapy with temozolomide
seemed to improve survival, but randomized trial is still needed
to test this hypothesis.
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